Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use
Endocrinology and Metabolism · 28.02.2025 · 40 (1) · 47-56
DOI: 10.3803/enm.2024.2125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 28.02.2025. Verfasst von Jeonghoon Ha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of…. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Osteoporotic Fractures. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Catholic Medical Center, National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Osteoporosis management in post-menopausal women focuses on fracture prevention, with denosumab as a key therapeutic option. Despite its proven efficacy in reducing fracture risk and increasing bone mineral density (BMD) over 10 years, its long-term impact remains uncertain. We evaluated the literature on its efficacy and safety beyond the initial decade. Clinical trials and real-world studies confirm denosumab’s sustained efficacy, especially in lumbar spine BMD, with hip BMD stabilizing. Concerns about adverse events (AEs) like hypocalcemia and osteonecrosis of the jaw necessitate vigilant monitoring. Risks of atypical femoral fractures and malignancies also require attention, despite unclear links to treatment duration. Clinical guidelines for denosumab beyond 10 years are limited, emphasizing the need for careful monitoring. In certain scenarios, such as advanced chronic kidney disease, prolonged denosumab may be required to balance AE risks with fracture prevention benefits. Denosumab shows potential for long-term efficacy in augmenting BMD; however, monitoring for AEs is crucial to guide clinical decision-making effectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Biostatistics, Korea University College of Medicine, Seoul, Korea.
- Medical Excellence Inc., Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Förderung
- Catholic Medical Center
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Ha, J., Lee, Y. J., Kim, J., Jeong, C., Lim, Y., Lee, J., Baek, K. H., & Catholic Medical Center Bone Research Group (2025). Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use. Endocrinology and Metabolism, 40(1), 47-56. https://doi.org/10.3803/enm.2024.2125
Vancouver
Ha J, Lee YJ, Kim J, Jeong C, Lim Y, Lee J, et al. Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use. Endocrinology and Metabolism. 2025;40(1):47-56. doi:10.3803/enm.2024.2125
BibTeX
@article{Ha2025,
author = {Ha, Jeonghoon and Lee, Youn-Ju and Kim, Jinyoung and Jeong, Chaiho and Lim, Yejee and Lee, Jeongmin and Baek, Ki-Hyun and Catholic Medical Center Bone Research Group, Catholic Medical Center Bone Research Group},
title = {Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use},
journal = {Endocrinology and Metabolism},
year = {2025},
volume = {40},
number = {1},
pages = {47--56},
doi = {10.3803/enm.2024.2125}
}
EUVIMED